Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

15-Year Follow-up of Protection and Immunity After Bivalent HPV Vaccination in Women (HPV Vaccine)

14. November 2026 aktualisiert von: Jun Zhang, Xiamen University

A 15-Year Follow-up Study of Long-Term Protection and Immunopersistence of an Escherichia Coli-Produced Bivalent HPV-16/18 Vaccine in Healthy Women Aged 18-45 Years

This study aims to evaluate the long-term protection provided by a bivalent HPV vaccine produced in Escherichia coli against specific clinical endpoints related to HPV types 16 and 18 in women aged 18-45 years, as well as the persistence of antibodies specific to these two HPV types.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This observational study is a long-term follow-up of participants in the phase III clinical trial of a bivalent HPV 16/18 vaccine produced in Escherichia coli (HPV-PRO-003, NCT01735006). Women aged 18-45 years at enrollment in the original trial were randomly assigned to receive either the HPV vaccine or a hepatitis E vaccine. The follow-up study will retain the original vaccine and control groups. No additional study intervention will be administered.

Through 15 years after the first dose, this study aims to evaluate the long-term protection provided by the bivalent HPV vaccine against specific clinical endpoints associated with HPV types 16 and/or 18 and to assess the persistence of antibodies specific to HPV types 16 and 18.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

2000

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Guangxi
      • Liuzhou, Guangxi, China, 545007
        • Liuzhou Center for Disease Control and Prevention
        • Kontakt:
    • Hebei
      • Fengning, Hebei, China, 068350
        • Fengning Hospital of Traditional Chinese Medicine
        • Kontakt:
    • Henan
      • Qingpingjie, Henan, China, 452370
        • Xinmi Maternal and Child Health Hospital
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind
  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Weiblich

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

The study population comprises women who received at least one dose of their assigned vaccine in the original phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003). To be eligible, women must not have received any HPV vaccine outside their original trial assignment since enrollment in that trial, including any subsequent catch-up doses given to control group participants. Participants retain their original group assignments (HPV vaccine group or hepatitis E vaccine control group).

Beschreibung

Inclusion Criteria:

  • The participant took part in the phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003) and received at least one dose of the vaccine assigned to her in that trial.
  • The participant has given informed consent and signed the consent form.
  • The participant is able to complete all study procedures as required by the protocol.

Exclusion Criteria:

  • Since enrollment in the original phase III trial, the participant has received any HPV vaccine other than the study vaccination assigned under the original trial protocol. This includes subsequent catch-up vaccination with the investigational vaccine among participants in the original control group, as well as receipt of any other licensed or unlicensed HPV vaccine.
  • The participant had an invasive malignancy of the cervix, vagina, or vulva before enrollment in this follow-up study, or an abnormality detected at screening is confirmed to be an invasive malignancy at one of these sites by histopathological examination of a colposcopy-directed biopsy specimen.
  • In the investigator's judgment, a medical, psychological, social, occupational, or other circumstance would interfere with the participant's ability to comply with the protocol or to provide written informed consent.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Vaccine group

Women assigned to the vaccine group in the original phase III trial who received at least one dose of the bivalent HPV 16/18 vaccine. Since enrollment in the original trial, they must not have received any HPV vaccine other than the study vaccine administered as specified in that trial's protocol. Participants must also meet all other eligibility criteria for this follow-up study.

The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant

Control group

Women assigned to the control group in the original phase III trial who received at least one dose of control vaccine (hepatitis E vaccine). Since enrollment in the original trial, they must not have received any HPV vaccine other than vaccination specified in the original trial protocol. Participants must also meet all other eligibility criteria for this follow-up study.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
CIN2+, VIN2+, or VaIN2+ associated with HPV type 16 or 18 in the per-protocol population
Zeitfenster: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 2 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
6-month persistent infection with HPV type 16 or 18 in the per-protocol population
Zeitfenster: At months 156 and 180 after the first dose in the original trial

Infection with the same HPV type must persist for at least 6 months

At months 156 and 180 after the first dose in the original trial

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
CIN1+, VIN1+, or VaIN1+ associated with HPV type 16 or 18
Zeitfenster: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 1 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
CIN2+ associated with HPV type 16 or 18
Zeitfenster: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 2 or worse cervical intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
VIN2+, or VaIN2+ associated with HPV type 16 or 18
Zeitfenster: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 2 or worse vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
HPV-16-specific infection and/or lesion endpoints
Zeitfenster: At months 156 and 180 after the first dose in the original trial

6-month persistent infection and grade 2 or worse cervical intraepithelial

At months 156 and 180 after the first dose in the original trial
HPV-18-specific infection and/or lesion endpoints
Zeitfenster: At months 156 and 180 after the first dose in the original trial

6-month persistent infection and grade 2 or worse cervical intraepithelial

At months 156 and 180 after the first dose in the original trial
Type-specific infection and/or lesion endpoints associated with other high-risk HPV types, including HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68
Zeitfenster: At months 156 and 180 after the first dose in the original trial

6-month persistent infection and grade 2 or worse cervical intraepithelial

At months 156 and 180 after the first dose in the original trial
Type-specific seropositivity rates for HPV-16 and HPV-18 antibodies
Zeitfenster: At months 156 and 180 after the first dose in the original trial

Percentage of participants seropositive for HPV-16 and HPV-18 antibodies

At months 156 and 180 after the first dose in the original trial
Type-specific HPV-16 and HPV-18 antibody levels
Zeitfenster: At months 156 and 180 after the first dose in the original trial

Serum antibody titers against HPV-16 and HPV-18

At months 156 and 180 after the first dose in the original trial

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
incident HPV-16 and/or HPV-18 infection
Zeitfenster: At months 156 and 180 after the first dose in the original trial

Newly detected HPV-16 and/or HPV-18 DNA positivity

At months 156 and 180 after the first dose in the original trial

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienstuhl: Jun Zhang, Xiamen University
  • Hauptermittler: Ting Wu, Xiamen University

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Januar 2027

Primärer Abschluss (Geschätzt)

31. Dezember 2029

Studienabschluss (Geschätzt)

31. Dezember 2029

Studienanmeldedaten

Zuerst eingereicht

14. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

14. November 2026

Zuerst gepostet (Tatsächlich)

19. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

19. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

14. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • HPV-PRO-003-4

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Beschreibung des IPD-Plans

Proposals should be sent to the Principal Investigator. Proposals will be reviewed and approved by the study team.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .